Palvella Secures FDA Pre-NDA Meeting for QTORIN ; Raises $230M Equity
Palvella Therapeutics announced significant progress in its clinical pipeline and strong financial positioning. The company secured an FDA Pre-NDA meeting for QTORIN rapamycin for microcystic lymphatic malformations, with NDA submission on track for the second half of 2026. This follows positive Phase 3 SELVA topline results and positions the company for potential U.S. commercial launch in H1 2027. Palvella also completed an oversubscribed $230.0 million equity financing, bolstering its balance sheet to $261.9 million in cash and equivalents as of March 31, 2026. The company reported a net loss of $15.8 million for Q1 2026, reflecting increased R&D and G&A expenses as it advances its pipeline and prepares for commercialization.
Key Highlights
- FDA Pre-NDA meeting granted for QTORIN rapamycin for microcystic lymphatic malformations, expected Q2 2026.
- NDA submission for QTORIN rapamycin for microcystic lymphatic malformations on track for H2 2026.
- Completed $230.0 million upsized, oversubscribed equity financing in February 2026.
- Cash, cash equivalents, and short-term investments were $261.9 million as of March 31, 2026.
- Net loss for Q1 2026 was $15.8 million, compared to $8.2 million in Q1 2025.
- R&D expenses for Q1 2026 increased to $9.3 million from $4.1 million in Q1 2025.
- Phase 3 trial for QTORIN rapamycin for cutaneous venous malformations planned for H2 2026.
- Phase 2 LOTU trial for QTORIN rapamycin for angiokeratomas initiated, topline results expected H2 2027.